Chinese medicine formula ‘Baipuhuang Keli’ inhibits triple-negative breast cancer by hindering DNA damage repair via MAPK/ERK pathway

Mi, Shichao; Liu, Xin; Zhang, Liufeng; Wang, Yifan; Sun, Li; Yuan, Shengtao; Cui, Min; Liu, Yanyan

doi:10.1016/j.jep.2022.116077

Cited by 7 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…195,[261][262][263][264] Timely DNA repair can greatly reduce the chance of cancer. 265 p53 can promote DNA damage repair and inhibit carcinogenesis by inducing factors such as DDB2, SESN1, and SESN2. DNA damage-induced high expression of p53 can activate DNA damage-binding protein 2 (DDB2), repair DNA damage, and inhibit cancer.…”

Section: P53 Promotes Dna Damage Repairmentioning

confidence: 99%

“…DNA damage repair refers to the phenomenon that DNA molecules in biological cells recover their structure after being damaged by a variety of enzymes, mainly including NER, base excision repair, mismatch repair, and DSB repair 195,261–264 . Timely DNA repair can greatly reduce the chance of cancer 265 . p53 can promote DNA damage repair and inhibit carcinogenesis by inducing factors such as DDB2, SESN1, and SESN2.…”

Section: Regulatory Mechanisms Of P53 On Downstream Genesmentioning

confidence: 99%

“… 195 , 261 , 262 , 263 , 264 Timely DNA repair can greatly reduce the chance of cancer. 265 p53 can promote DNA damage repair and inhibit carcinogenesis by inducing factors such as DDB2, SESN1, and SESN2.…”

Section: Regulatory Mechanisms Of P53 On Downstream Genesmentioning

confidence: 99%

See 2 more Smart Citations

Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies

Shen¹,

Wang²,

Mao³

et al. 2023

MedComm

View full text Add to dashboard Cite

Tumor suppressor p53 can transcriptionally activate downstream genes in response to stress, and then regulate the cell cycle, DNA repair, metabolism, angiogenesis, apoptosis, and other biological responses. p53 has seven functional domains and 12 splice isoforms, and different domains and subtypes play different roles. The activation and inactivation of p53 are finely regulated and are associated with phosphorylation/acetylation modification and ubiquitination modification, respectively. Abnormal activation of p53 is closely related to the occurrence and development of cancer. While targeted therapy of the p53 signaling pathway is still in its early stages and only a few drugs or treatments have entered clinical trials, the development of new drugs and ongoing clinical trials are expected to lead to the widespread use of p53 signaling‐targeted therapy in cancer treatment in the future. TRIAP1 is a novel p53 downstream inhibitor of apoptosis. TRIAP1 is the homolog of yeast mitochondrial intermembrane protein MDM35, which can play a tumor‐promoting role by blocking the mitochondria‐dependent apoptosis pathway. This work provides a systematic overview of recent basic research and clinical progress in the p53 signaling pathway and proposes that TRIAP1 is an important therapeutic target downstream of p53 signaling.

show abstract